. Author manuscript; available in PMC: 2021 Oct 29.

Published in final edited form as: Cancer Treat Rev. 2012 Apr 19;39(1):27–43. doi: 10.1016/j.ctrv.2012.03.007

Table 4.

Predictive markers of response to therapy.

Tumor	Predictive marker	Status
NSCLC	Disease stage	JBR.10 trial: primary benefit in stage II disease with tumor >4 cm²⁶
		ANITA: primary benefit in stage II and IIIA disease²⁴
	Tumor ERCC1 levels	Under investigation
	EGFR mutations	Under investigation
	Genetic signature ‘lung Metagene model’	Under investigation¹⁶⁰
Colon cancer	Microsatellite instability	Poor outcome in microsatellite instability-high tumors^161,162
Osteosarcoma, Ewing’s sarcoma, soft tissue sarcoma	Risk classification based on specific histologic subtypes, tumor grade, location and patient characteristics
Osteosarcoma, Ewing’s sarcoma, soft tissue sarcoma	Molecular signatures	Under investigation^163,164
Melanoma	Disease stage	Greater benefits in micrometastatic vs. macrometastatic nodal disease^108,109
Melanoma	Ulceration of primary tumor	Greater benefits in patients with ulcerated vs. non-ulcerated primary tumor¹⁶⁵
Breast cancer	Oncotype DX^™ 21-gene assay	Predicts risk of recurrence in patients treated with tamoxifen, identifies patients who will obtain most benefit from adjuvant tamoxifen and those who might derive greater benefit from chemotherapy vs. tamoxifen¹⁶
Breast cancer	Mammaprint 70-gene assay	Predicts which patients may benefit most from adjuvant chemotherapy